Article Text

Download PDFPDF
Bleeding during percutaneous intervention: tailoring the approach to minimise risk
  1. T Kinnaird1,
  2. R Anderson1,
  3. J Hill2,
  4. M Thomas3
  1. 1
    University Hospital Wales, Cardiff, UK
  2. 2
    Kings College Hospital, London, UK
  3. 3
    St Thomas' Hospital, London, UK
  1. Dr T Kinnaird, Department of Cardiology, University Hospital of Wales, Heath Park, Cardiff, UK; tim.kinnaird{at}cardiffandvale.wales.nhs.uk

Abstract

The incidence of ischaemic complications during percutaneous intervention (PCI) has reduced over recent years. As a result, bleeding has now emerged as one of the most common complications of PCI in contemporary practice. In addition, measures intended to minimise ischaemic complications—such as balloon pumps or glycoprotein inhibitors—may actually increase bleeding frequency. Recent studies have not only highlighted the incidence with which major bleeding occurs but also demonstrated the profound effect of bleeding on mortality. Thus bleeding can no longer be considered an irritation that can simply be ignored or transfused. This review summarises the major trial and registry data obtained in a PubMed search combining the terms “bleeding” and “percutaneous coronary intervention” and then proposes strategies to minimise bleeding occurrence.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Competing interests: TK has been reimbursed by Nycomed Pharmaceuticals for attending several meetings and also received speakers fees from Nycomed Pharmaceuticals. MT has received speakers fees from Nycomed Pharmaceuticals.